27 August 2015 - Novartis Canada has filed a submission with CADTH for Jakavi (ruxolitinib phosphate) for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. Jakavi has not yet been registered by Health Canada for this new indication. A date for its consideration by the pERC has not yet been set.

For more details, go to: https://www.cadth.ca/ruxolitinib-jakavi-polycythemia-vera-details